We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

OKE:NYSEONEOK, Inc. Analysis

Data as of 2026-05-23 - not real-time

$94.03

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

ONEOK is trading at $94.03, comfortably above its 20‑day (≈90.16) and 50‑day (≈88.68) moving averages and well above the 200‑day level (≈78.13), confirming a strong bullish trend. The RSI of 61 and a bullish MACD histogram (+0.50) further underscore upward momentum, while the price sits just below the identified resistance at $96.07, suggesting limited upside in the very short term. Analyst sentiment is upbeat, with a consensus “Buy” rating from 21 analysts and a median price target of $94, reflecting confidence in the stock’s near‑term trajectory.
Fundamentally, OKE delivers robust top‑line growth of nearly 20% YoY, a PE of 16.8 that is well under the industry average of 21.6, and a dividend yield of 4.55% backed by a 74% payout ratio. Despite a hefty debt load (DE/Equity ≈150%) the company generates solid operating cash flow (~$5.6 B) and modest free cash flow, supporting dividend sustainability. Recent Q1 earnings beat expectations on EBITDA, and the company raised its 2026 guidance, reinforcing the bullish narrative while the high‑yield dividend remains a key attraction for income‑focused investors.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish technicals (price above SMAs, bullish MACD)
  • Analyst upgrades and raised guidance
  • High dividend yield attracting income investors

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong revenue growth (~20% YoY)
  • Undervalued relative to industry PE
  • Sustainable cash flow supporting dividend and debt service

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Elevated debt-to-equity ratio posing balance‑sheet risk
  • Stable midstream business model with low beta exposure
  • Consistent dividend income but limited growth beyond mid‑term

Key Metrics & Analysis

Financial Health

Revenue Growth19.60%
Profit Margin10.03%
P/E Ratio16.8
ROE15.90%
ROA5.66%
Debt/Equity149.64
P/B Ratio2.6
Op. Cash Flow$5.6B
Free Cash Flow$454.4M
Industry P/E21.6

Technical Analysis

TrendBullish
RSI61.6
Support$83.66
Resistance$96.07
MA 20$90.16
MA 50$88.68
MA 200$78.13
MACDBullish
VolumeDecreasing
Fear & Greed Index91.61

Valuation

Target Price$95.00
Upside/Downside1.03%
GradeUndervalued
TypeBlend
Dividend Yield4.55%

Risk Assessment

Beta-0.12
Volatility29.04%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.